Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MERTK | Q12866 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 3/20 | 0.41 |
| ▸ | TXNRD1 | Q16881 | 3/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PGK1 | P00558 | 1/20 | 0.40 |
| ▸ | RPS6KB2 | Q9UBS0 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27246111 | 0.85 | MAPT (0.62) | MAPTHTTFGFR4ALDH1A1MAPK1 | |
| SCHEMBL29925033 | 0.83 | MAPT (0.60) | MAPTHTTFGFR4ALDH1A1MAPK1 | |
| SCHEMBL30154422 | 0.83 | MAPT (0.67) | MAPTHTTFGFR4MAPK1TDP1 | |
| SCHEMBL1978817 | 0.83 | MAPT (0.67) | MAPTHTTFGFR4MAPK1TDP1 | |
| SCHEMBL11355207 | 0.81 | MAPT (0.61) | MAPTHTTFGFR4ALDH1A1TDP1 | |
| SCHEMBL27211667 | 0.80 | MAPT (0.68) | MAPTHTTFGFR4CYP1A2CYP2C9 | |
| SCHEMBL28489676 | 0.80 | TXNRD1 (0.53) | MAPTHTTMAPK1GSRTXNRD1 | |
| SCHEMBL3995132 | 0.79 | MAPT (0.62) | MAPTHTTFGFR4ALDH1A1CYP1A2 | |
| SCHEMBL28946168 | 0.78 | MAPT (0.60) | MAPTHTTFGFR4MAPK1TDP1 | |
| SCHEMBL1242494 | 0.78 | MAPT (0.59) | MAPTHTTFGFR4MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140302174-A1 | Combination Therapy for Ovarian Cancer | ELI LILLY AND COMPANY | 2014-10-09 | — | — | US | disclosed |
| EP-2780011-A1 | COMBINATION THERAPY FOR OVARIAN CANCER | Eli Lilly and Company (US) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013070460-A1 | COMBINATION THERAPY FOR OVARIAN CANCER | ELI LILLY AND COMPANY (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140302174-A1 | Combination Therapy for Ovarian Cancer | PAICS, FOLR2, TYMP | MAPT 4672/4885HTT 2812/4885FGFR4 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.